Peptide and protein biomarkers for type 1 diabetes mellitus
A method for identifying persons with increased risk of developing type 1 diabetes mellitus, or having type I diabetes mellitus, utilizing selected biomarkers described herein either alone or in combination. The present disclosure allows for broad based, reliable, screening of large population bases. Also provided are arrays and kits that can be used to perform such methods.
1. A method of detecting peptides in a human blood sample, comprising:
determining a quantity of at least eight peptides selected from the group consisting of the amino acid sequence shown in SEQ ID NO: 23, 24, 25, 37, 38, 39, 40, 41, 47, 48, 49, 50, 51, and 52 in the blood sample obtained from the human, wherein at least one of the eight peptides consists of the amino acid sequence shown in SEQ ID NO: 25, 38, 39, 40, or 50; and
comparing the quantity of the at least eight peptides to a control representing expression for each of the at least eight peptides expected in a subject who does not have type 1 diabetes mellitus (T1DM); and
determining if there is differential expression of the at least eight peptides between the blood sample and the control.
2. The method of claim 1 wherein the method comprises determining a quantity of all 14 peptides consisting of the amino acid sequence shown in SEQ ID NO: 23, 24, 25, 37, 38, 39, 40, 41, 47, 48, 49, 50, 51, and 52.
3. The method of claim 1 wherein determining a quantity of the at least eight peptides consists of determining a quantity of the peptides consisting of the amino acid sequence shown in SEQ ID NO: 37, 38, 39, 41, 47, 48, 49, and 50.
4. The method of claim 1 wherein the method comprises determining a quantity of at least eight peptides consisting of the amino acid sequence shown in SEQ ID NO: 37, 38, 39, 41, 47, 48, 49, and 50.
5. The method of claim 1 wherein determining the quantity of the at least 8 peptides comprises determining a quantity of at least one peptide consisting of the amino acid sequence shown in SEQ ID NO: 25, 38, 39, 40, or 50, in addition to a peptide sequence consisting of;
NIQSLEVIGK (SEQ ID NO: 41);
LLDSLPSDTR (SEQ ID NO: 48);
NIQSLEVIGK (SEQ ID NO: 41) and LLDSLPSDTR (SEQ ID NO: 48);
FQPTLLTLPR (SEQ ID NO: 47);
LVLLNAIYLSAK (SEQ ID NO: 49);
TNLESILSYPK (SEQ ID NO: 50);
FQPTLLTLPR (SEQ ID NO: 47), LLDSLPSDTR (SEQ ID NO: 48), LVLLNAIYLSAK (SEQ ID NO: 49), and TNLESILSYPK (SEQ ID NO: 50);
NIQSLEVIGK (SEQ ID NO: 41), FQPTLLTLPR (SEQ ID NO: 47), LLDSLPSDTR (SEQ ID NO: 48), LVLLNAIYLSAK (SEQ ID NO: 49), and TNLESILSYPK (SEQ ID NO: 50), or
combinations thereof.
6. The method of claim 1 , wherein determining the quantity of the at least eight peptides comprises determining the quantity of at least one of the eight peptides consisting of the amino acid sequence shown in SEQ ID NO: 25, 38, 39, 40, or 50, wherein at least one of eight peptides are SEQ ID NO: 38 and 39, and the quantity of the peptide consisting of the amino acid sequence shown in SEQ ID NO: 37 is also determined.
7. The method of claim 1 , wherein the blood sample is a serum or plasma sample.
8. The method of claim 1 , wherein determining a quantity comprises a qualitative or quantitative determination.
9. The method of claim 1 , wherein determining the quantity of at least eight peptides comprises analyzing the blood sample using liquid chromatography multiple reaction monitoring mass spectrometry (LC-MRM-MS).
10. The method of claim 1 , wherein the determining step and/or the comparing step are performed on a suitably programmed computer.
11. The method of claim 1 , further comprising providing an output showing the quantity of the at least eight peptides compared to the control.